Outcome of Board meeting

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

APLLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.5%Reaction day

₹785.00

prior close

₹780.50

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.4%-0.2% vs market

Pharmaceuticals peers, median of 160sector-0.1%-0.4% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.0

10m

+0.9

15m

+0.8

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.5-0.4-0.2-0.1-0.4

Next day

-7.5-1.7-5.8-0.9-6.7

-4.1-1.3-2.8-0.2-3.9

-4.5-0.7-3.8+0.3-4.8

-4.6+0.4-5.0+1.1-5.7

-3.6+0.5-4.1+0.2-3.8

-3.3+2.8-6.1+1.0-4.3

15d

-4.9+1.2-6.1-0.2-4.7

-5.9+5.3-11.2+1.7-7.6

+8.6+9.9-1.3+7.7+0.9

+4.9+13.1-8.2+8.1-3.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alembic Pharmaceuticals reported standalone revenue of Rs 6,651 crore for FY2026, up 10.3% from Rs 6,033 crore in FY2025. Profit after tax grew 27.3% to Rs 640 crore versus Rs 503 crore previously. Consolidated revenue was Rs 7,345 crore (up 10.1%) with PAT of Rs 675 crore (up 15.7%). Net profit margin expanded from 8.34% to 9.63% on standalone basis. The Board recommended dividend of Rs 12 per share (600%) versus Rs 11 (550%) earlier. Key exceptional items included Rs 48.64 crore charge for labour code implementation, Rs 18.35 crore write-down on Sikkim facility assets held for sale, and Rs 100.27 crore deferred tax asset recognition from tax rate changes. Statutory auditors issued unmodified opinion on both standalone and consolidated results.

Likely market impact

Strong profitability growth with PAT up 27% on standalone basis and margin expansion signals operational efficiency gains. Increased dividend demonstrates confidence in financial health. Conservative debt levels (Debt-Equity 0.20) and positive operating cash flow of Rs 809 crore support shareholder returns.